9th Annual Accelerating Anticancer Agent Development and Validation Workshop

Discounted Rates Available for NCI SBIR Grantees at the 9th Annual Accelerating Anticancer Agent Development and Validation Workshop
May 16-18, 2012

The National Cancer Institute (NCI) invites you to attend the 9th annual Accelerating Anticancer Agent Development and Validation Workshop May 16-18, 2012 in Bethesda, MD. NCI SBIR grantees interested in attending will receive a reduced academic rate of $500 for one representative per company. The workshop will focus on expediting the development and validation process for new anticancer and cancer prevention agents. Additionally, the NCI SBIR Development Center will lead a discussion focused on ways to leverage NCI SBIR funding opportunities to develop and advance anticancer agents on May 17 from 3:00-5:00pm.

NCI SBIR Discussion: Using the NCI Small Business Innovation Research Program to Advance Anticancer Agents
May 17, 2012, 3:00-5:00pm EDT
Bethesda North Marriott Hotel and Conference Center
5701 Marinelli Road
Bethesda, MD 20852

NCI SBIR program directors will lead an in-depth workshop on making the most of SBIR funding and initiatives, including case studies of successful awardees that highlight how to best navigate opportunities, challenges, and critical decision points.

Please email ncisbir@mail.nih.gov if you are interested in more information or meeting with a program director during the workshop.

NCI SBIR grantees interested in attending will receive a reduced academic rate of $500 for one representative per company. The regular corporate rate of $1,375 applies for all other attendees. Please contact Mary Ruemker at mary.ruemker@duke.edu for additional details and to register.

Add this event to your calendar.

Additional Details:

The Accelerating Anticancer Agent Development and Validation Workshop is designed to bring together leaders in clinical and translational cancer research from academia, industry, NCI, and FDA to assist investigators in understanding and improving the process of cancer drug development. This is an intensive and interactive workshop designed to promote effective strategies – from clinical trial initiatives, to enabling trials, to pivotal efficacy trials – leading to the development of new anticancer and prevention agents.

To learn more about this workshop, please visit: http://www.acceleratingworkshop.org/index.php.

The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.

Sign up to receive updates about
SBIR & STTR funding opportunities at
sbir.cancer.gov

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: